Publications (original articles or review articles) published in 2021 from OUS - Department of Clinical Cancer Research
18 publications found
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621
Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score
Transpl Int, 34 (9), 1722-1732
DOI 10.1111/tri.13981, PubMed 34448271
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
Br J Cancer, 126 (5), 726-735
DOI 10.1038/s41416-021-01620-6, PubMed 34887523
Metastases in locally advanced rectal cancer undergoing curatively intended treatment
Eur J Surg Oncol, 47 (9), 2377-2383
DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
Br J Cancer, 125 (2), 240-246
DOI 10.1038/s41416-021-01377-y, PubMed 33837301
Burkitt Lymphoma International Prognostic Index
J Clin Oncol, 39 (10), 1129-1138
DOI 10.1200/JCO.20.03288, PubMed 33502927
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
J Neuroendocrinol, 33 (5), e12967
DOI 10.1111/jne.12967, PubMed 33769624
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
Br J Cancer, 126 (7), 1010-1017
DOI 10.1038/s41416-021-01657-7, PubMed 34903842
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Clin Cancer Res, 27 (10), 2755-2763
DOI 10.1158/1078-0432.CCR-20-3435, PubMed 33542073
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
J Clin Oncol, 39 (4), 273-284
DOI 10.1200/JCO.20.02088, PubMed 33503393
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol, 28 (9), 5252-5262
DOI 10.1245/s10434-021-10022-0, PubMed 34019185
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
Prostate, 82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 29 (1), 1-14
DOI 10.1530/ERC-21-0152, PubMed 34647903
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Lancet Respir Med, 9 (6), 613-621
DOI 10.1016/S2213-2600(20)30515-4, PubMed 33836153
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877